Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
2021 · Journal for ImmunoTherapy of Cancer · 92 citations
https://doi.org/10.1136/jitc-2020-001696
D
Desheng Weng
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
80
Papers
2.2K
Citations
26
h-index
50
i10-index
Desheng Weng is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immune Cell Function and Interaction & Immunotherapy and Immune Responses. The author has an h-index of 26, co-authored 68 publications.
Papers by this author
worksPhase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma
2023 · Cell Reports Medicine · 44 citations
https://doi.org/10.1016/j.xcrm.2023.101133
Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma
2023 · BMC Medicine · 34 citations
https://doi.org/10.1186/s12916-023-03016-0
Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma
2018 · Cancer Management and Research · 31 citations
https://doi.org/10.2147/cmar.s181949
Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin
2021 · Cell Death and Disease · 29 citations
https://doi.org/10.1038/s41419-021-04375-3
Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial
2023 · EClinicalMedicine · 28 citations
https://doi.org/10.1016/j.eclinm.2023.102240
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat